New opportunities in the management and treatment of refractory hypercholesterolemia using in vivo CRISPR-mediated genome/base editing
Nutrition, Metabolism and Cardiovascular Diseases · 2023
DOI: 10.1016/j.numecd.2023.08.010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2023. Verfasst von Rai Ajit K Srivastava. Beteiligte Einrichtung: Integrated Pharma Solutions, Boston, USA; Northeastern University, Boston, USA. Electronic address: ajitsriva@gmail.com. Hauptthemen laut MEDLINE: Hypercholesterolemia, Homozygous Familial Hypercholesterolemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 128 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Integrated Pharma Solutions, Boston, USA; Northeastern University, Boston, USA. Electronic address: ajitsriva@gmail.com.
Zitieren
APA
Srivastava, R. A. K. (2023). New opportunities in the management and treatment of refractory hypercholesterolemia using in vivo CRISPR-mediated genome/base editing. Nutrition, Metabolism and Cardiovascular Diseases. https://doi.org/10.1016/j.numecd.2023.08.010
Vancouver
Srivastava RAK. New opportunities in the management and treatment of refractory hypercholesterolemia using in vivo CRISPR-mediated genome/base editing. Nutrition, Metabolism and Cardiovascular Diseases. 2023. doi:10.1016/j.numecd.2023.08.010
BibTeX
@article{Srivastava2023,
author = {Srivastava, Rai Ajit K},
title = {New opportunities in the management and treatment of refractory hypercholesterolemia using in vivo CRISPR-mediated genome/base editing},
journal = {Nutrition, Metabolism and Cardiovascular Diseases},
year = {2023},
doi = {10.1016/j.numecd.2023.08.010}
}
EUVIMED